{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:09:41Z","timestamp":1790932181193,"version":"4.1.0"},"reference-count":59,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The purpose of this paper is to review human leukocyte antigen G (HLA-G) in the eye, its role in immune tolerance, and the potential therapeutic use of AAV gene transfer and expression of HLA-G in various ocular tissues. Several studies are reviewed that demonstrate efficacy in animal models of disease, including intracorneal delivery of AAV-HLA-G to treat corneal inflammation and prevent corneal graft rejection, subconjunctival injection of AAV-HLA-G for ocular graft vs. host disease and potentially dry eye disease, and intravitreal injection of AAV-HLA-G to inhibit uveitis. Furthermore, due to the anti-vascular function of HLA-G, AAV-HLA-G may be an effective therapy for posterior ocular diseases, such as neovascular age-related macular degeneration, diabetic retinopathy, and choroidal neovascularization. Therefore, AAV-mediated gene transfer of HLA-G may be an effective treatment for common immune-mediated, inflammatory, and neovascular diseases of the eye.<\/jats:p>","DOI":"10.3390\/ijms23073465","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:20:25Z","timestamp":1648038025000},"page":"3465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Therapeutic Applications of Adeno-Associated Virus (AAV) Gene Transfer of HLA-G in the Eye"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7771-9166","authenticated-orcid":false,"given":"Brian C.","family":"Gilger","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, North Carolina State University, Raleigh, NC 27607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Ophthalmology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08830180212066","article-title":"Anterior Chamber Associated Immune Deviation (ACAID): Regulation, Biological Relevance, and Implications for Therapy","volume":"21","author":"Streilein","year":"2002","journal-title":"Int. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni1328","article-title":"See No Evil, Hear No Evil, Do No Evil: The Lessons of Immune Privilege","volume":"7","author":"Niederkorn","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000099253","article-title":"Immune Privilege and Angiogenic Privilege of the Cornea","volume":"92","author":"Cursiefen","year":"2007","journal-title":"Immune Response Eye"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.7150\/ijbs.49890","article-title":"The Role of Inflammation in Age-Related Macular Degeneration","volume":"16","author":"Tan","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic Side Effects of Eye Drops: A Pharmacokinetic Perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical Review: Topical Ophthalmic Use of Cyclosporin A","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bastola, P., Song, L., Gilger, B.C., and Hirsch, M.L. (2020). Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12080767"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering Adeno-Associated Virus Vectors for Gene Therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2015.00009","article-title":"The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases","volume":"6","author":"Dias","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"796054","DOI":"10.3389\/fimmu.2022.796054","article-title":"HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease","volume":"13","author":"Juarez","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13816810.2018.1533027","article-title":"Gene Therapy for RPE65-Related Retinal Disease","volume":"39","author":"Coussa","year":"2018","journal-title":"Ophthalmic Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/gt.2017.59","article-title":"Spinraza\u2014A Rare Disease Success Story","volume":"24","author":"Prakash","year":"2017","journal-title":"Gene Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17840","DOI":"10.1038\/s41598-017-18002-9","article-title":"AAV Vector-Meditated Expression of HLA-G Reduces Injury-Induced Corneal Vascularization, Immune Cell Infiltration, and Fibrosis","volume":"7","author":"Hirsch","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_14","first-page":"3317","article-title":"AAV Vector-Mediated HLA-G Expression to Prevent Corneal Transplant Rejection","volume":"59","author":"Gilger","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_15","first-page":"798","article-title":"Immunomodulatory Gene Therapy for Treatment of Ocular Graft vs. Host Disease","volume":"62","author":"Nilles","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19864","DOI":"10.1038\/s41598-019-56462-3","article-title":"AAV-Mediated Expression of HLA-G1\/5 Reduces Severity of Experimental Autoimmune Uveitis","volume":"9","author":"Crabtree","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G","volume":"Volume 127","author":"Carosella","year":"2015","journal-title":"Advances in Immunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1182\/blood-2005-12-019919","article-title":"Soluble HLA-G1 Inhibits Angiogenesis through an Apoptotic Pathway and by Direct Binding to CD160 Receptor Expressed by Endothelial Cells","volume":"108","author":"Fons","year":"2006","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.humimm.2003.08.346","article-title":"Expression of HLA-G in Human Cornea, an Immune-Privileged Tissue","volume":"64","author":"Moreau","year":"2003","journal-title":"Hum. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2370.1999.00145.x","article-title":"HLA-G and Classical HLA Class I Transcripts in Various Components of the Adult Human Eye: HLA Transcripts in the Human Eye","volume":"26","author":"Robert","year":"1999","journal-title":"Eur. J. Immunogenet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.humimm.2017.04.007","article-title":"Expression and Differential Regulation of HLA-G Isoforms in the Retinal Pigment Epithelial Cell Line, ARPE-19","volume":"78","author":"Svendsen","year":"2017","journal-title":"Hum. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1096\/fj.04-2078rev","article-title":"HLA-G and Immune Tolerance in Pregnancy","volume":"19","author":"Hunt","year":"2005","journal-title":"FASEB J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1073\/pnas.89.9.3947","article-title":"Alternative Splicing of HLA-G Transcripts Yields Proteins with Primary Structures Resembling Both Class I and Class II Antigens","volume":"89","author":"Ishitani","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/JLB.3MIR0817-337R","article-title":"Negative Regulators That Mediate Ocular Immune Privilege","volume":"103","author":"Taylor","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"B\u00f6hringer, D., Grotejohann, B., Ihorst, G., Reinshagen, H., Spierings, E., and Reinhard, T. (2018). Rejection Prophylaxis in Corneal Transplant. Dtsch. Aerzteblatt Online.","DOI":"10.3238\/arztebl.2018.0259"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ACI.0b013e32833dfa11","article-title":"High Risk Corneal Allografts and Why They Lose Their Immune Privilege","volume":"10","author":"Niederkorn","year":"2010","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1542-0124(11)70035-0","article-title":"Anti-VEGF Treatment of Corneal Neovascularization","volume":"9","author":"Keating","year":"2011","journal-title":"Ocul. Surf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal Neovascularization: An Anti-VEGF Therapy Review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.10.11.11","article-title":"Characteristics of Toxic Keratopathy, an In Vivo Confocal Microscopy Study","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108272","DOI":"10.1016\/j.exer.2020.108272","article-title":"Corneal Myofibroblasts and Fibrosis","volume":"201","author":"Wilson","year":"2020","journal-title":"Exp. Eye Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamaophthalmol.2015.4776","article-title":"Global Survey of Corneal Transplantation and Eye Banking","volume":"134","author":"Gain","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.survophthal.2017.12.008","article-title":"Angiogenesis and Lymphangiogenesis in Corneal Transplantation\u2014A Review","volume":"63","author":"Zhong","year":"2018","journal-title":"Surv. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/ICO.0b013e3181ca321c","article-title":"Ocular Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation","volume":"29","author":"Westeneng","year":"2010","journal-title":"Cornea"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41409-018-0340-0","article-title":"Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT","volume":"54","author":"Inamoto","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1167\/iovs.02-0699","article-title":"Periductal Area as the Primary Site for T-Cell Activation in Lacrimal Gland Chronic Graft-versus-Host Disease","volume":"44","author":"Ogawa","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.ophtha.2016.02.044","article-title":"A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease","volume":"123","author":"Abud","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bbmt.2012.05.016","article-title":"Clinical Benefit of Response in Chronic Graft-versus-Host Disease","volume":"18","author":"Inamoto","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1167\/iovs.19-27843","article-title":"Graft versus Host Disease-Associated Dry Eye: Role of Ocular Surface Mucins and the Effect of Rebamipide, a Mucin Secretagogue","volume":"60","author":"Shamloo","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exer.2016.11.004","article-title":"Assessment of Dry Eye in a GVHD Murine Model: Approximation through Tear Osmolarity Measurement","volume":"154","author":"Ramos","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.bbmt.2016.07.012","article-title":"Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model","volume":"22","author":"Perez","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41434-018-0035-6","article-title":"Serotype Survey of AAV Gene Delivery via Subconjunctival Injection in Mice","volume":"25","author":"Song","year":"2018","journal-title":"Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ilar\/ily002","article-title":"Immune Relevant Models for Ocular Inflammatory Diseases","volume":"59","author":"Gilger","year":"2018","journal-title":"ILAR J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000119867","article-title":"Equine Recurrent Uveitis\u2014A Spontaneous Horse Model of Uveitis","volume":"40","author":"Deeg","year":"2008","journal-title":"Ophthalmic Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/09273948.2014.968671","article-title":"The Manchester Uveitis Clinic: The First 3000 Patients, 2: Uveitis Manifestations, Complications, Medical and Surgical Management","volume":"23","author":"Jones","year":"2015","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cca.2010.04.017","article-title":"Uveitis: Mechanisms and Recent Advances in Therapy","volume":"411","author":"Srivastava","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2011.11.004","article-title":"Interplay between Innate and Adaptive Immunity in the Development of Non-Infectious Uveitis","volume":"31","author":"Willermain","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_49","first-page":"994","article-title":"Prevention of Experimental Autoimmune Uveitis by Intravitreal AAV-EqIL-10","volume":"62","author":"Crabtree","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/09273948.2012.726392","article-title":"Gene Therapy for Noninfectious Uveitis","volume":"20","author":"Chu","year":"2012","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/mt.2015.30","article-title":"Gene Therapy with the Caspase Activation and Recruitment Domain Reduces the Ocular Inflammatory Response","volume":"23","author":"Ildefonso","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"31912","DOI":"10.1038\/srep31912","article-title":"AAV8-Mediated Angiotensin-Converting Enzyme 2 Gene Delivery Prevents Experimental Autoimmune Uveitis by Regulating MAPK, NF-\u039aB and STAT3 Pathways","volume":"6","author":"Qiu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-1-60761-720-4_22","article-title":"Rodent Models of Experimental Autoimmune Uveitis","volume":"Volume 900","author":"Perl","year":"2012","journal-title":"Autoimmunity"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ddmod.2006.03.005","article-title":"Animal Models of Autoimmune and Immune-Mediated Uveitis","volume":"3","author":"Caspi","year":"2006","journal-title":"Drug Discov. Today Dis. Models"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I\/IIa Trial by Intravitreal Delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omtm.2021.05.011","article-title":"Characterizing the Cellular Immune Response to Subretinal AAV Gene Therapy in the Murine Retina","volume":"22","author":"Chandler","year":"2021","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.62.2.41","article-title":"Characterization of Gene Therapy Associated Uveitis Following Intravitreal Adeno-Associated Virus Injection in Mice","volume":"62","author":"Tummala","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV Cis-Regulatory Sequences Are Correlated with Ocular Toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:41:21Z","timestamp":1760136081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/7\/3465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23073465"],"URL":"https:\/\/doi.org\/10.3390\/ijms23073465","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}